The effect of amphotericin B derivatives on Leishmania and immune functions

Journal of Parasitology

Volumn 91, Issue 1, 2005, Pages 158-163

  Ehrenfreund Kleinman, Tirtsa ^a   Domb, Abraham J ^a   Jaffe, Charles L ^a,b   Nasereddin, Abed ^a,b   Leshem, Benni ^a,c   Golenser, Jacob ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MINISTRY OF HEALTH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ARABINOGALACTAN; CHOLESTEROL; CONCANAVALIN A; ERGOSTEROL; GAMMA INTERFERON; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; AMPHOTERICIN B ARABINOGALACTAN CONJUGATE; AMPHOTERICIN B-ARABINOGALACTAN CONJUGATE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; GALACTAN; REACTIVE OXYGEN METABOLITE;

IMMUNE RESPONSE; LEISHMANIASIS;

AMASTIGOTE; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEISHMANIA TROPICA; LYMPHOCYTE ACTIVATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN SECRETION; PROTEIN SYNTHESIS; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOASSAY; CHEMOLUMINESCENCE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PARASITOLOGY; PERITONEUM MACROPHAGE;

LEISHMANIA (PROPER);

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; B-LYMPHOCYTES; BIOLOGICAL ASSAY; CHEMILUMINESCENT MEASUREMENTS; GALACTANS; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LEISHMANIA TROPICA; LYMPHOCYTE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MONOCYTES; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17844385560     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-3379     Document Type: Article

References (36)

1. AL MOFLEH, I. A., A. A. MAHMOUD, A. S. AL KHUWAITER, AND A. S. AL TUWAIJRI. 1989. Effect of Leishmania major on luminol-dependent chemiluminescence of human whole blood phagocytosis. Tropical Medicine and Parasitology 40: 279-284.
2. AZZAM, T., H. ELIYAHU, L. SHAPIRA, M. LINIAL, Y. BARENHOLZ, AND A. J. DOMB. 2002. Polysaccharide-oligoamine based conjugates for gene delivery. Journal of Medicinal Chemistry 45: 1817-1824.
3. BECKER, I., P. VOLKOW, O. VELASCO CASTREJON, N. SALAIZA SUAZO, M. BERZUNZA CRUZ, J. S. DOMINGUEZ, A. MORALES VARGAS, A. RUIZ REMIGIO, AND R. PEREZ MONTFORT. 1999. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitology Research 85: 165-170.
4. BLACKWELL, J. M. 1999. Tumour necrosis factor alpha and mucocutaneous leishmaniasis. Parasitology Today 15: 73-75.
5. BOGDAN, C., AND M. ROLLINGHOFF. 1998. The immune response to Leishmania: Mechanisms of parasite control and evasion. International Journal for Parasitology 28: 121-134.
6. BRAJTBURG, J., W. G. POWDERLY, G. S. KOBAYASHI, AND G. MEDOFF. 1990. Amphotericin B: Current understanding of mechanisms of action. Antimicrobial Agents and Chemotherapy 34: 183-188.
7. BUTLER, W. T. 1966. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. Journal of the American Medical Association 195: 371-375.
8. DASGUPTA, S., A. MOOKERJEE, S. K. CHOWDHURY, AND A. C. GHOSE. 1999. Immunosuppression in hamsters with progressive visceral leishmaniasis: An evaluation of the role of nitric oxide toward impairment of the lymphoproliferative response. Parasitology Research 85: 594-596.
9. DING, A. H., C. F. NATHAN, AND D. J. STUEHR. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. Journal of Immunology 141: 2407-2412.
10. EHRENFREUND KLEINMAN, T., T. AZZAM, R. FALK, I. POLACHECK, J. GOLENSER, AND A. J. DOMB. 2002. Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Biomaterials 23: 1327-1335.
11. FALK, R., A. J. DOMB, AND I. POLACHECK. 1999. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrobial Agents and Chemotherapy 43: 1975-1981.
12. FOWELL, D. J., M. BIX, K. SHINKAI, D. LACY, AND R. M. LOCKSLEY. 1998. Disease susceptibility and development of the cytokine repertoire in the murine Leishmania major model. European Cytokine Network 9: 102-106.
13. GALLIS, H. A., R. H. DREW, AND W. W. PICKARD. 1990. Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 12: 308-329.
14. GOLENSER, J., S. FRANKENBURG, T. EHRENFREUND, AND A. J. DOMB. 1999. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrobial Agents and Chemotherapy 43: 2209-2214.
15. HAUER, J., AND F. A. ANDERER. 1993. Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis. Cancer Immunology and Immunotherapy 36: 237-244.
16. JOSHI, M., D. M. DWYER, AND H. L. NAKHASI. 1993. Cloning and characterization of differentially expressed genes from in vitro-grown amastigotes of Leishmania-donovani. Molecular and Biochemical Parasitology 58: 345-354.
17. JUTTNER, S., J. BERNHAGEN, C. N. METZ, M. ROLLINGHOFF, R. BUCALA, AND A. GESSNER. 1998. Migration inhibitory factor induces killing of Leishmania major by macrophages: Dependence on reactive nitrogen intermediates and endogenous TNF-alpha. Journal of Immunology 161: 2383-2390.
18. KELLY, G. S. 1999. Larch arabinogalactan: Clinical relevance of a novel immune-enhancing polysaccharide. Alternative Medical Reviews 4: 96-103.
19. KOLE, L., L. DAS, AND P. K. DAS. 1999. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. Journal of Infectious Diseases 180: 811-820.
20. LUETTIG, B., C. STEINMULLER, G. E. GIFFORD, H. WAGNER, AND M. L. LOHMANN MATTHES. 1989. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. Journal of National Cancer Institute 81: 669-675.
21. MADDUX, M. S., AND S. L. BARRIERE. 1980. A review of complications of amphotericin-B therapy: Recommendations for prevention and management. Drug Intelligence and Clinical Pharmacy 14: 177-181.
22. MAUEL, J., AND A. RANSIJN. 1997. Leishmania spp.: Mechanisms of toxicity of nitrogen oxidation products. Experimental Parasitology 87: 98-111.
23. MOZAFFARIAN, N., J. W. HERMAN, AND A. CASADEVALL. 1997. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrobial Agents and Chemotherapy 41: 1825-1829.
24. MURRAY, H. W. 2000. Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches. International Journal of Infectious Diseases 4: 158-177.
25. -, AND C. F. NATHAN. 1999. Macrophage microbicidal mechanisms in vivo: Reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. The Journal of Experimental Medicine 189: 741-746.
26. NIEDBALA, W., X. Q. WEI, D. PIEDRAFITA, D. XU, AND F. Y. LIEW. 1999. Effects of nitric oxide on the induction and differentiation of Th1 cells. European Journal of Immunology 29: 2498-505.
27. PRESCOTT, J. H., P. ENRIQUEZ, C. JUNG, E. MENZ, AND E. V. GROMAN. 1995. Larch arabinogalactan for hepatic drug delivery: Isolation and characterization of a 9 kDa arabinogalactan fragment. Carbohydrate Research 278: 113-128.
28. ROGERS, P. D., J. K. JENKINS, S. W. CHAPMAN, K. NDEBELE, B. A. CHAPMAN, AND J. D. CLEARY. 1998. Amphotericin B activation of human genes encoding for cytokines. Journal of Infectious Diseases 178: 1726-1733.
29. SABRA, R., AND R. A. BRANCH. 1990. Amphotericin B nephrotoxicity. Drug Safety 5: 94-108.
30. SUNDAR, S., F ROSENKAIMER, M. L. LESSER, AND H. W. MURRAY. 1995. Immunochemotherapy for a systemic intracellular infection: Accelerated response using interferon-gamma in visceral leishmaniasis. Journal of Infectious Diseases 171: 992-996.
31. TAYLOR, A. P., AND H. W. MURRAY. 1998. Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis. Journal of Infectious Diseases 178: 908-911.
32. THAKUR, C. P., S. NARAIN, N. KUMAR, S. M. HASSAN, D. K. JHA, AND A. KUMAR. 1997. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Annals of Tropical Medicine and Parasitology 91: 611-616.
33. TOHYAMA, M., K. KAWAKAMI, AND A. SAITO. 1996. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrobial Agents and Chemotherapy 40: 1919-1923.
34. TOKUDA, Y., M. TSUJI, M. YAMAZAKI, S. KIMURA, S. ABE, AND H. YAMAGUCHI. 1993. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrobial Agents and Chemotherapy 37: 2228-2230.
35. VONK, A. G., M. G. NETEA, N. E. DENECKER, I. C. VERSCHUEREN, J. W. VAN DER MEER, AND B. J. KULLBERG. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. Journal of Antimicrobial Chemotherapy 42: 469-474.
36. YAMAGUCHI, H., S. ABE, AND Y. TOKUDA. 1993. Immunomodulating activity of antifungal drugs. Annals of the New York Academy of Sciences 685: 447-457.